Related references
Note: Only part of the references are listed.Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
Vatche Tchekmedyian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
Laura D. Locati et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
Allen S. Ho et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A clinically validated comprehensive companion diagnostic platform for care of patients with advanced cancer
James X. Sun et al.
CANCER RESEARCH (2018)
Phase II trial of apatinib in patients with recurrent and/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis.
Guopei Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Patrick M. Dillon et al.
CLINICAL CANCER RESEARCH (2017)
Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma
David W. Sant et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
A. L. Ho et al.
ANNALS OF ONCOLOGY (2016)
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
L. D. Locati et al.
EUROPEAN JOURNAL OF CANCER (2016)
PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).
Joel Guigay et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.
Alan Loh Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
Bhumsuk Keam et al.
CANCER (2015)
Genomic landscape of adenoid cystic carcinoma of the breast
Luciano G. Martelotto et al.
JOURNAL OF PATHOLOGY (2015)
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
David J. Thomson et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
Dong-Wan Kim et al.
BMC CANCER (2014)
Whole exome sequencing of adenoid cystic carcinoma
Philip J. Stephens et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
The mutational landscape of adenoid cystic carcinoma
Allen S. Ho et al.
NATURE GENETICS (2013)
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
N. G. Chau et al.
ANNALS OF ONCOLOGY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands
Mark Agulnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
